CLRB Stock Summary and Trading Ideas (Cellectar Biosciences | NASDAQ:CLRB)

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Cellectar Biosciences trades on the NASDAQ stock market under the symbol CLRB.

As of January 9, 2026, CLRB stock price declined to $3.08 with 92,889 million shares trading.

CLRB has a beta of 0.79, meaning it tends to be less sensitive to market movements. CLRB has a correlation of 0.02 to the broad based SPY ETF.

CLRB has a market cap of $13.06 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CLRB traded as high as $133.50 and as low as $2.45.

The top ETF exchange traded funds that CLRB belongs to (by Net Assets): VTI, VXF.

CLRB has underperformed the market in the last year with a return of -67.0%, while the SPY ETF gained +19.0%. In the last 3 month period, CLRB fell short of the market, returning -35.4%, while SPY returned +3.7%. However, in the most recent 2 weeks CLRB has outperformed the stock market by returning +20.3%, while SPY returned +0.5%.

CLRB support price is $3.05 and resistance is $3.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLRB shares will trade within this expected range on the day.